AbbVie (ABBV)
282.75
-6.33 (2.19%)
Upcoming Events
Latest Headlines
Allergan Aesthetics presents eight posters at AMWC Dubai
October 21, 2026 8:02 AM - StreetInsider
Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence
October 21, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $325 at Barclays
October 21, 2026 3:15 AM - StreetInsider
AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
October 20, 2026 7:55 AM - PR NewsWire
AbbVie's ABBV-466 shows higher remission rates in Crohn's trial
October 19, 2026 6:01 AM - StreetInsider
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Diseas
October 19, 2026 4:00 AM - PR NewsWire
/C O R R E C T I O N - AbbVie/
October 18, 2026 9:18 PM - PR NewsWire
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
October 18, 2026 6:10 PM - PR NewsWire
AbbVie presents long-term IBD drug data at European gastroenterology meeting
October 17, 2026 8:17 AM - StreetInsider
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
October 17, 2026 2:00 AM - PR NewsWire
AbbVie expands board to 13, appoints UC San Diego health chief
October 15, 2026 4:03 PM - StreetInsider
Form 8-K AbbVie Inc. For: Oct 14
October 15, 2026 4:01 PM - SEC Filing
AbbVie Skyrizi shows endoscopic gains in Crohn's disease trial
October 13, 2026 3:15 PM - StreetInsider
AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
October 13, 2026 3:15 PM - PR NewsWire
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
October 11, 2026 1:00 PM - PR NewsWire
Abbvie (ABBV) PT Raised to $275 at UBS
October 9, 2026 9:06 AM - StreetInsider
Abbvie (ABBV) PT Raised to $300 at JPMorgan
October 8, 2026 8:09 AM - StreetInsider
Abbvie (ABBV) PT Raised to $290 at Cantor Fitzgerald
October 8, 2026 7:10 AM - StreetInsider
FDA grants AbbVie's Temab-A two breakthrough therapy designations
October 7, 2026 8:32 AM - StreetInsider
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
October 7, 2026 8:30 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $310 at Morgan Stanley
October 7, 2026 7:57 AM - StreetInsider
UBS Reiterates Neutral Rating on Abbvie (ABBV)
October 6, 2026 9:11 AM - StreetInsider
Abbvie (ABBV) PT Raised to $320 at Scotiabank
October 6, 2026 8:10 AM - StreetInsider
Genmab stock surges 11% on positive cancer drug trial data
October 5, 2026 4:30 PM - StreetInsider
AbbVie updates 2026 earnings guidance with Q3 R&D charges
October 5, 2026 4:16 PM - StreetInsider
Form 8-K AbbVie Inc. For: Oct 05
October 5, 2026 4:08 PM - SEC Filing
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell
October 5, 2026 2:55 PM - PR NewsWire
Genmab and AbbVie drug cuts lymphoma progression risk by 51%
October 5, 2026 2:53 PM - StreetInsider
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell
October 5, 2026 2:49 PM - StreetInsider
Form 4 AbbVie Inc. For: Sep 30 Filed by: RAPP EDWARD J
October 2, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: Sep 30 Filed by: Quaggin Susan E
October 2, 2026 5:00 PM - SEC Filing
AbbVie Rinvoq shows continued skin repigmentation at 76 weeks
October 1, 2026 10:01 AM - StreetInsider
AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
October 1, 2026 10:00 AM - PR NewsWire
AbbVie to Host Third-Quarter 2026 Earnings Conference Call
October 1, 2026 8:00 AM - PR NewsWire
AbbVie presents 60 dermatology abstracts at 2026 EADV Congress
September 30, 2026 6:00 AM - StreetInsider
AbbVie Phase 1 data shows weight loss with monthly obesity drug
September 30, 2026 5:45 AM - StreetInsider
AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
September 30, 2026 5:45 AM - PR NewsWire
AbbVie Phase 2 eczema drug meets primary endpoint in trial
September 30, 2026 1:30 AM - StreetInsider
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
September 30, 2026 1:30 AM - PR NewsWire
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
September 30, 2026 1:00 AM - PR NewsWire
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
September 29, 2026 9:00 AM - PR NewsWire
FDA approves AbbVie's tavapadon for Parkinson's disease
September 28, 2026 8:00 AM - StreetInsider
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
September 28, 2026 8:00 AM - PR NewsWire
Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach
September 22, 2026 8:00 AM - PR NewsWire
EU approves AbbVie's Rinvoq for children with joint disease
September 22, 2026 6:02 AM - StreetInsider
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
September 22, 2026 2:00 AM - PR NewsWire
AbbVie strikes multi-year AI drug discovery deal with Iambic
September 21, 2026 8:02 AM - StreetInsider
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
September 21, 2026 8:00 AM - PR NewsWire
AbbVie presents real-world Vraylar data at Psych Congress 2026
September 18, 2026 8:31 AM - StreetInsider
AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
September 18, 2026 8:30 AM - PR NewsWire
AbbVie to present Phase 3 etentamig data at myeloma meeting
September 17, 2026 8:30 AM - StreetInsider
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
September 17, 2026 8:30 AM - PR NewsWire
Allergan Aesthetics releases small skin study on GLP-1 medication users
September 17, 2026 8:01 AM - StreetInsider
Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
September 17, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) Reiterated at Overweight by Cantor Fitzgerald on Zumilokibart Promise
September 16, 2026 7:41 AM - StreetInsider
AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign
September 15, 2026 8:30 AM - PR NewsWire
Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit
September 15, 2026 8:00 AM - PR NewsWire
AbbVie (ABBV) Declares $1.73 Quarterly Dividend; 2.7% Yield
September 10, 2026 2:19 PM - StreetInsider
AbbVie Declares Quarterly Dividend
September 10, 2026 2:18 PM - PR NewsWire
AbbVie atogepant meets all endpoints in menstrual migraine Phase 3 trial
September 10, 2026 8:55 AM - StreetInsider
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
September 10, 2026 8:55 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $315 at HSBC
September 10, 2026 3:28 AM - StreetInsider
Abbvie (ABBV) PT Raised to $282 at BofA Securities
September 8, 2026 5:50 AM - StreetInsider
AbbVie's etentamig meets Phase 3 endpoints in multiple myeloma trial
September 3, 2026 9:15 AM - StreetInsider
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multi
September 3, 2026 9:15 AM - PR NewsWire
Form 8-K AbbVie Inc. For: Sep 03
September 3, 2026 8:48 AM - SEC Filing
AbbVie completes $10.9B acquisition of Apogee Therapeutics
September 3, 2026 8:35 AM - StreetInsider
AbbVie Completes Acquisition of Apogee Therapeutics
September 3, 2026 8:35 AM - PR NewsWire
AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
September 3, 2026 8:05 AM - PR NewsWire
Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care
September 2, 2026 8:00 AM - PR NewsWire
SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
September 1, 2026 8:05 AM - PR NewsWire
AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
August 31, 2026 8:00 AM - PR NewsWire
AbbVie seeks EMA approval for Skyrizi subcutaneous use in Crohn's
August 27, 2026 6:00 AM - StreetInsider
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
August 27, 2026 2:00 AM - PR NewsWire
AbbVie lung cancer drug data shows high response rates at WCLC 2026
August 21, 2026 7:45 AM - StreetInsider
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
August 21, 2026 7:45 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $303 at Piper Sandler
August 20, 2026 7:22 AM - StreetInsider
Form 4 AbbVie Inc. For: Aug 14 Filed by: Donoghoe Nicholas
August 18, 2026 5:00 PM - SEC Filing
Form 8-K AbbVie Inc. For: Aug 18
August 18, 2026 4:31 PM - SEC Filing
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
August 18, 2026 12:57 PM - Globe NewsWire
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
August 18, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $300 at Wells Fargo
August 17, 2026 6:26 AM - StreetInsider
Form 144 AbbVie Inc. Filed by: Donoghoe Nicholas
August 14, 2026 4:40 PM - SEC Filing
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
August 13, 2026 9:26 AM - StreetInsider
Wolfe Research Upgrades Abbvie (ABBV) to Outperform
August 13, 2026 5:35 AM - StreetInsider
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
August 12, 2026 9:15 AM - StreetInsider
Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
August 11, 2026 8:01 AM - PR NewsWire
Form 424B5 AbbVie Inc.
August 6, 2026 5:08 PM - SEC Filing
Form 8-K AbbVie Inc. For: Aug 04
August 5, 2026 5:17 PM - SEC Filing
Erste Group Upgrades Abbvie (ABBV) to Buy
August 5, 2026 9:51 AM - StreetInsider
Form FWP AbbVie Inc. Filed by: AbbVie Inc.
August 5, 2026 6:04 AM - SEC Filing
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
August 4, 2026 9:05 AM - StreetInsider
Form 424B5 AbbVie Inc.
August 4, 2026 8:19 AM - SEC Filing
FDA accepts AbbVie's Botox Cosmetic application for jaw slimming use
August 4, 2026 8:01 AM - StreetInsider
Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
August 4, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $288 at Guggenheim
August 4, 2026 6:49 AM - StreetInsider
Form 10-Q AbbVie Inc. For: Jun 30
August 3, 2026 2:14 PM - SEC Filing
Abbvie (ABBV) PT Raised to $285 at Cantor Fitzgerald
August 3, 2026 9:19 AM - StreetInsider
Abbvie (ABBV) PT Raised to $296 at Morgan Stanley
August 3, 2026 8:17 AM - StreetInsider
Abbvie (ABBV) PT Raised to $290 at Canaccord
August 3, 2026 6:41 AM - StreetInsider
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
August 1, 2026 10:00 AM - StreetInsider
AbbVie shares fall on earnings miss and weak guidance
July 31, 2026 8:12 AM - StreetInsider
Form 8-K AbbVie Inc. For: Jul 31
July 31, 2026 7:51 AM - SEC Filing
AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
July 31, 2026 7:49 AM - StreetInsider
AbbVie Reports Second-Quarter 2026 Financial Results
July 31, 2026 7:47 AM - PR NewsWire
AbbVie Q2 earnings preview: analysts eye immunology growth, pipeline
July 30, 2026 11:30 PM - StreetInsider
AbbVie (ABBV) call put ratio 1 call to 1 put into quarter results
July 30, 2026 11:01 AM - StreetInsider
JUVÉDERM® Day Returns to U.S. on August 19
July 30, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $300 at Barclays
July 29, 2026 5:19 AM - StreetInsider
EU approves AbbVie's Rinvoq for severe alopecia areata
July 29, 2026 3:00 AM - StreetInsider
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
July 29, 2026 3:00 AM - PR NewsWire
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
July 29, 2026 3:00 AM - PR NewsWire
Genmab and AbbVie say epcoritamab trial missed U.S. survival goal
July 23, 2026 4:00 PM - StreetInsider
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
July 23, 2026 4:00 PM - StreetInsider
Full Article List
